Dr Reddys Laboratories (RDY) Long-Term Deferred Tax (2009 - 2026)

Dr Reddys Laboratories has reported Long-Term Deferred Tax for 18 years, with the latest figure at $244.7 million in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 13.45% year-over-year to $244.7 million in Q2 2026; TTM through Jun 2026 was $244.7 million, a 13.45% decrease from a year earlier, with the FY2026 full-year figure at $239.0 million, up 10.14% from the prior year.
• Long-Term Deferred Tax was $244.7 million for Q2 2026 at Dr Reddys Laboratories, roughly flat from $245.4 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $282.7 million in Q2 2025, with the low at $76.8 million in Q4 2022.
• Average Long-Term Deferred Tax over 5 years is $171.3 million, with a median of $154.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax tumbled 33.3% in 2022, then surged 70.7% in 2023.
• Over 5 years, Long-Term Deferred Tax stood at $76.8 million in 2022, then soared by 70.7% to $131.1 million in 2023, then soared by 65.06% to $216.4 million in 2024, then rose by 10.25% to $238.6 million in 2025, then gained by 2.56% to $244.7 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $244.7 million (Q2 2026), $245.4 million (Q1 2026), and $238.6 million (Q4 2025), per Business Quant data.